Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Christie Hospital NHS Trust, Manchester, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:2City/State/Province:Manchester
Treatments:ChemotherapyHospital:Christie Hospital NHS Trust
Drugs:Journal:Link
Date:Jul 2005

Description:

Patients: This Phase II study involved 17 patients with advanced non-small-cell lung cancer. Eleven patients were men, and six were women. The median age was 62 years, and none of the patients had chemotherapy before this study.

Treatment: The treatment consisted of one chemotherapeutic agent: RFS2000 (rubitecan).

Toxicity: The authors stated that adverse events were typically mild to moderate and included grade 1-2 toxicities: diarrhea, nausea, anorexia, and lethargy.

Results: The median overall survival was 8.4 months (257 days), but there were no responses to this treatment. The authors cited the low dosage given to the patients as the reason.

Correspondence: Sofia Baka, MD



Back